A viral protein called ORF8 tricks immune cells into becoming gateways for infection, driving the runaway lung inflammation of severe COVID — and pointing to an existing drug that might interrupt it.
Lilly’s Inluriyo plus Verzenio is now cleared for ER-positive, HER2-negative breast cancer with an ESR1 mutation — a resistance driver — after a trial showed switching to the combo doubled how long the cancer stayed in check.
Ahead of a pivotal advisory meeting, FDA staff flagged no major problems with GRAIL’s Galleri — a single blood test that hunts for signals of dozens of cancers, many with no screening today.
With more than 3,000 dead in the fastest-spreading Ebola outbreak on record, the DRC has begun giving frontline health workers an existing vaccine — used compassionately, because it wasn’t designed for this strain.
Beacon’s one-time eye gene therapy improved low-light vision in men with X-linked retinitis pigmentosa — the first pivotal trial in this blinding disease to hit its main goal.
The deal pairs Telix’s targeted cancer therapies with ITM’s ability to make the scarce radioactive isotopes the whole field depends on — a bid to own more of a fast-growing, supply-constrained business.
A soft, flexible fiber less than half a millimeter wide combines three tools neuroscientists usually need separate devices for — a design meant to work with the brain instead of irritating it.
A concentrated compound called 7-OH — barely present in the natural kratom leaf but abundant in new commercial products — is driving opioid-like dependence and harsh withdrawal, clinics say.
A new rule swaps the term “animal tests” for “nonclinical tests,” formally recognizing lab-on-a-chip, human-cell and AI methods as valid ways to gauge a drug’s safety — without banning animal studies.
Pooling 69 trials and 150,000-plus adults, researchers found routine calcium and vitamin D supplements did little to prevent fractures or falls — with important exceptions for people who are deficient or have osteoporosis.
Olivia and Tom Walton have committed an initial $100M to Healthy Moms, Healthy Babies America. The money is small next to the problem — which is exactly why it is structured as matching capital.
A new electronic artificial urinary sphincter lets men restore bladder control at the push of a key-fob button — a potential upgrade over devices that require an awkward manual squeeze. Early results are promising, but the study is tiny.